Pfizer
on Tuesday laid out steering for the 2023 fiscal 12 months very well under Wall Street consensus figures, tempering investor anticipations in advance of what it expects to be a steep drop in Covid-19 item sales.
Shares fell 3% in premarket trading on the downbeat direction.
#Pfizer #Inventory #Falls #Downbeat #Direction #Corporation #Braces #Covid #Vaccine #DropOff